Clinical trials: Macular Oedema
Neovascular Age-related Macular Degeneration, Macular Oedema Secondary to RVO
A Trial to Evaluate the Safety and Usability of the SB15 PFS in Trial Participants With AMD, Macular Oedema Secondary to RVO, or Diabetic Macular Oedema
This is an open label, multicenter, Phase II trial to evaluate the safety and usability of the pre-filled syringe (PFS) of SB15 (Aflibercept biosimilar).
- Conditions
- Neovascular Age-related Macular Degeneration, Macular Oedema Secondary to RVO, Diabetic Macular Oedema
- Trial name
- NCT07844343
- Testing
- SB15 PFS
- Where
- 3 sites in South Korea
- Volunteers
- 33 people
- Sponsor
- Samsung Bioepis Co., Ltd.
Severe Diabetic Macular Oedema
Anti-vascular Endothelial Growth Factor (Anti-VEGF) Monotherapy vs Anti-VEGF Followed by Subthreshold Micropulse Laser for Treating Severe Diabetic Macular Oedema When the Central Retina Goes <400 Microns
The macula is the centre of the retina; it gives central sight, colour and fine detail. People with diabetes may develop diabetic macular oedema (DMO).
- Trial name
- DAME (NCT06985706)
- Testing
- Subthreshold Micropulse Laser (SML), Anti-VEGF Monotherapy (standard care)
- Where
- 22 sites in United Kingdom
- Volunteers
- 264 people
- Sponsor
- Belfast Health and Social Care Trust
Diabetic Macular Oedema
Applied Conversion Equation for Optical Coherence Tomography
The investigator wants to investigate how big the differences are between measurements of the back of the eye taken by different OCT machines.
- Trial name
- ACE-OCT (NCT07816627)
- Testing
- Optical coherence tomography scan
- Where
- United Kingdom
- Volunteers
- 338 people
- Sponsor
- Gloucestershire Hospitals NHS Foundation Trust
Diabetic Macular Oedema
A Study to Evaluate the Efficacy and Safety of IBI302 inSubjects With Diabetic Macular Edema（DME）
The study is designed for multi-center,randomized,double-masked,active-contralledstudy to evaluate effective and security of intravitrealinjection of IBI302 in subjects with Diabetic Macular Oedema.
- Trial name
- NCT06908876
- Testing
- IBI302, Faricimab
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Innovent Biologics Technology Limited (Shanghai R&D Center)
Macular Oedema, Cataract Surgery
Comparing Efficacy of Bromfenac 0.09%, Nepafenac 0.3% and Diclofenac 0.1% in Patients After Cataract Surgery
The goal of this clinical trial is to learn which of the drugs bromfenac 0.09%, nepafenac 0.3% and diclofenac 0.1% has better efficacy in treatment and prevention of cystoid macular oedema after cataract surgery.
- Conditions
- Macular Oedema, Cataract Surgery, NSAID (Non-Steroidal Anti-Inflammatory Drug)
- Trial name
- BND (NCT07178639)
- Testing
- Bromfenac 0.09 % Ophthalmic Solution, Nepafenac 0.3% Oph Susp, diclofenac 0.1% ophthalmic susp.
- Where
- Czechia
- Volunteers
- 150 people
- Sponsor
- Nemocnice Kolín
Epiretinal Membrane, Macular Oedema
Evaluation of Retinal Parameters in Patients With Epiretinal Membrane After Vitrectomy
The goal of this interventional study is to assess the dynamics of structural and functional retinal changes in eyes with epiretinal membrane (ERM) after pars plana vitrectomy (PPV).
- Conditions
- Epiretinal Membrane, Macular Oedema, Macular Diseases, Retinal Diseases
- Trial name
- NCT07165626
- Testing
- Subtreshold micropulse laser therapy, Pars plana vitrectomy
- Where
- Poland
- Volunteers
- 100 people
- Sponsor
- Pomeranian Medical University Szczecin
Diabetic Macular Oedema, Retinal Vein Occlusion with Macular Oedema
Safety and Efficacy of IBE-814 Intravitreal (IVT) Implant - a Sustained, Low Dose Dexamethasone Therapy
This trial is a phase II, multi-center, single-masked (assessors) dose-ranging study designed to evaluate the comparative safety and preliminary efficacy of two dosage regimens of the IBE-814 IVT Dexamethasone Implant in patients…
- Trial name
- NCT04576689
- Testing
- IBE-814 70ug, IBE-814 140ug
- Where
- 21 sites in Australia, Canada and 2 more
- Volunteers
- 60 people
- Sponsor
- Ripple Therapeutics Pty Ltd
Diabetic Macular Oedema
The Use of ARA290 for the Treatment of Diabetic Macular Oedema
ARA 290-DMO is a prospective, open label, interventional, single centre, investigator led, phase II trial to examine the effect of ARA 290 on diabetic macular oedema in patients with type 1 or 2 diabetes.
- Trial name
- ARA290DMO (NCT06626971)
- Testing
- ARA290
- Where
- United Kingdom
- Volunteers
- 9 people
- Sponsor
- Belfast Health and Social Care Trust
Macular Oedema, Retinitis Pigmentosa
Aflibercept for Macular Oedema With Underlying Retinitis Pigmentosa (AMOUR) Study
The purpose of this study is to assess the safety and efficacy of intravitreal injections of Aflibercept (Eylea) in treating Cystoid Macula Oedema (CMO) in patients with underlying Retinitis Pigmentosa (RP).
- Trial name
- AMOUR (NCT02661711)
- Testing
- Aflibercept
- Where
- United Kingdom
- Volunteers
- 30 people
- Sponsor
- Moorfields Eye Hospital NHS Foundation Trust
Diabetic Macular Oedema
Noctura400 Treatment for Diabetic Retinopathy (CANDLE)
In this study, the investigators aim to use light masks (Noctura 400) to test the hypothesis that preventing the dark adaptation and associated hypoxia of the rods in the eye could in turn prevent or halt the progression of…
- Trial name
- CANDLE (NCT02207712)
- Testing
- Noctura 400 Eye Mask, Ranibizumab
- Where
- 18 sites in United Kingdom
- Volunteers
- 252 people
- Sponsor
- PolyPhotonix Medical
Pseudophakic Cystoid Macular Oedema, Epiretinal Membrane
Epiretinal Membrane and Cystoid Macular Oedema Post-cataract Surgery
This study examines whether the presence of an epiretinal membrane affects the time to resolution, requirement for non-topical treatment, and outcome of pseudophakic cystoid macular oedema.
- Trial name
- EPIC (NCT03965078)
- Testing
- topical (eye drop) anti-inflammatories
- Where
- United Kingdom
- Volunteers
- 123 people, healthy volunteers welcome
- Sponsor
- Portsmouth Hospitals NHS Trust
Diabetic Macular Oedema
Sub-threshold Photocoagulation of Diabetic Macular Oedema
Topcon's Endpoint Management (EM) is a new software from the Pascal® laser which allows us to decrease the intensity of the burns (invisible burns) showing some landmarks with normal intensity so the investigators can see the…
- Trial name
- MEM (NCT02309476)
- Testing
- PASCAL Laser, Green Laser 0.75, PASCAL Laser, Green Laser 1, PASCAL Laser, 70% Yellow Laser 0.75
- Where
- United Kingdom
- Sponsor
- Manchester University NHS Foundation Trust
Diabetic Macular Oedema
Near Infrared Photobiomodulation Treatment for Diabetic Macular Oedema
This pilot study aims to establish that treatment with near infrared light (NIR) reduces diabetic macular oedema in patients suffering diabetic retinopathy by exerting a positive beneficial effect at retinal cellular level.
- Trial name
- NIRD (NCT02181400)
- Testing
- Ellex Integre NIR laser
- Where
- Australia
- Volunteers
- 21 people
- Sponsor
- University of Sydney
Chronic Diabetic Macular Oedema Considered Insufficiently Responsive to Available Therapies
Iluvien Registry Safety Study
The study will include any patient treated with Iluvien at designated sites in European countries where marketing authorization has been granted in order to obtain broader safety and usage information.
- Trial name
- IRISS (NCT01998412)
- Where
- United States
- Volunteers
- 559 people
- Sponsor
- Alimera Sciences
Diabetic Macular Oedema
Aflibercept anD navigateD vErsus coNvensional Laser in Diabetic macUlar edeMa
Diabetic macular edema (DME) in diabetic retinopathy (DR) is the leading cause of visual impairment among the 300,000 Danish patients with diabetes (DM) and will in time affect 29% of patients.
- Trial name
- ADDENDUM (NCT02554747)
- Testing
- Navigated laser, Conventional laser
- Where
- Denmark
- Volunteers
- 48 people
- Sponsor
- Odense University Hospital
Diabetic Macular Oedema, Parafoveal Scotoma
Effectiveness of Training in Reading Rehabilitation for Patients With Diabetic Macular Oedema
Diabetic macular oedema (DMO) is a sight-threatening problem for diabetic patient who has swelling in macula. Patients with DMO can receive laser treatment and achieve good acuity finally.
- Trial name
- NCT02457884
- Testing
- Temporal Group, Spatial Group, Combined Group
- Where
- China
- Volunteers
- 55 people
- Sponsor
- The Hong Kong Polytechnic University
Diabetic Macular Oedema
Study of OZURDEX® in the Treatment of Diabetic Macular Oedema (DME) in Australia - The AUSSIEDEX Study
This prospective study will assess Ozurdex in the treatment of Diabetic Macular Oedema in clinical practice.
- Trial name
- NCT02731911
- Testing
- dexamethasone intravitreal implant
- Where
- 23 sites in Australia
- Volunteers
- 202 people
- Sponsor
- Allergan
Diabetes, Diabetic Macular Oedema
Trial of Switching Between Intravitreal Bevacizumab (Avastin®)& Intravitreal Dexamethasone (Ozurdex™) for Persistent Diabetic Macular Oedema
The specific aim of the study is to test the following hypothesis: That switching between treatments from bevacizumab to Ozurdex or vice versa in eyes with diabetic macular oedema with no or incomplete response from one therapy…
- Conditions
- Diabetes, Diabetic Macular Oedema, Diabetic Macular Edema, Diabetic Retinopathy
- Trial name
- SwitchDMO (NCT01787669)
- Testing
- Avastin (Bevacizumab), Ozurdex (dexamethasone)
- Where
- 3 sites in Australia
- Volunteers
- 19 people
- Sponsor
- University of Sydney
Diabetic Macular Oedema
To Evaluate the Comparative Efficacy of Lucentis (Ranibizumab) 0.5mg Intravitreal Injection in Patients With Diabetic Macular Oedema (DME) With Well Controlled and Poorly Controlled Diabetes Mellitus
To demonstrate the comparative effectiveness of 12 months of Lucentis (ranibizumab) in patients with well controlled compared to those with poorly controlled diabetes using an PRN treatment schedule.
- Trial name
- CONTROL (NCT03495765)
- Testing
- Ranibizumab
- Where
- Australia
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- Marsden Eye Specialists
Neovascular AMD, Visual Impairment Due to DME, Visual Impairment Due to Macular Oedema Secondary to Branch or Central RVO, Visual Impairment Due to CNV
Observation of Treatment Patterns With Lucentis in Approved Indications
A multicentre, open-label, non-interventional study to observe treatment patterns in patients with wet age-related macular degeneration (wAMD), with visual impairment due to diabetic macular edema (DME), due to macular edema…
- Trial name
- OCEAN (NCT02194803)
- Where
- Germany
- Volunteers
- 5,778 people
- Sponsor
- Novartis Pharmaceuticals